MiMedx says US FDA's warning letter for Axiofill not related to safety
Dec 29 (Reuters) - MiMedx Group MDXG.O said on Friday the U.S. Food and Drug Administration's warning letter for its recently launched placental-derived tissue product Axiofill was not related to safety. (Reporting by Sriparna Roy in Bengaluru; Editing by Shounak Dasgupta) ((Sriparna.Roy@thomsonreuters.com))
Recent news on MiMedx
See all newsMiMedx Q1 sales fall 33%, miss estimates, cuts 2026 outlook
Brief: MiMedx Q1 Sales USD 58.991 Million Vs. IBES Estimate USD 65 Million
MiMedx beats Q4 sales estimates; announces $100 mln share buyback
Brief: MiMedx Q4 Sales USD 118.095 Million Vs. IBES Estimate USD 106.8 Million
MiMedx Q3 net sales beat estimates